| Identification | Back Directory | [Name]
(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide | [CAS]
15533-09-2 | [Synonyms]
Compound C108
Compound C108 >=98% (HPLC)
Compound C108,Compound C-108
Compound C108, 10 mM in DMSO
2-Hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide
(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide
2-hydroxy-benzoicacid,2-[1-(2-hydroxyphenyl)ethylidene]hydrazide
Benzoic acid, 2-hydroxy-, 2-[1-(2-hydroxyphenyl)ethylidene]hydrazide | [Molecular Formula]
C15H14N2O3 | [MDL Number]
MFCD00565556 | [MOL File]
15533-09-2.mol | [Molecular Weight]
270.28 |
| Chemical Properties | Back Directory | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF:1.0(Max Conc. mg/mL);3.7(Max Conc. mM)
DMSO:1.0(Max Conc. mg/mL);3.7(Max Conc. mM) | [form ]
powder | [pka]
8.27±0.35(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
2-Hydroxy-benzoic Acid [1-(2-Hydroxyphenyl)ethylidene]hydrazide is a GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2) inhibitor. G3BP2 is involved with breast tumor initiation. | [Biochem/physiol Actions]
C108 is a small molecule that exhibits cancer-selective cytotoxicity (Viability = 100%/MCF-10A vs. 50%/BT-474, 67%/4T1, 70%/MDA-MB-231 & MDA-MB-453 post 48 h 1 μM C108 treatment) and synergizes with low dose paclitaxel in reducing ALDH-positive tumor-initiating cells (TIC poulation = 56.6%/control, 60.6%/0.1 μM paclitaxel alone, 47.4%/1 μM C108 alone, 7.3%/combined treatment for 24 h in BT474 breast cancer cultures) by targeting stress granule-associated protein G3BP2 (GAP SH3 domain-binding protein 2). Likewise, C108 pretreatment prior to xenografting greatly reduces BT-474 tumor-initiating frequency (from 1/175 to 1/1103 by limiting dilution xenograft assays) in mice in vivo. G3BP2 is reported to bind and stabilize SART3 mRNA, thereby indirectly regulating the core pluripotency transcription factors Oct-4 and Nanog critically involved in ESC self-renewal and breast tumor initiation. | [in vivo]
Compound C108 (1 μM; 24 h) targets and decreases tumor initiating cells (TICs), while injected BT-474 cells treated with Compound C108 into the mammary fat pad of female nonobese diabetic/severe combined immune deficiency (NOD-SCID) mice in a limiting-dilution xenograft assay[1]. |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
nanjing
|
| Tel: |
13376082704 13376082704 |
| Website: |
www.linye-e.com/ |
|